FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2747947255> ?p ?o ?g. }

• W2747947255 abstract "e15089 Background: Sunitinib is a first-line therapy for patients (pts) with aRCC. As a multitargeted tyrosine kinase inhibitor (TKI), it is associated with toxicities that may impact dosing; dose reductions may result in inferior clinical outcomes (Motzer, 2011 ASCO GU, abstract LBA308). This retrospective study was initiated by USON to evaluate dosing patterns of first-line sunitinib, and its association with toxicities and outcomes in community practices. Methods: Pts with aRCC who started first-line sunitinib between June 1, 2007 and May 31, 2011 at 17 USON practices were identified; clinical data were extracted by chart review from iKnowMed electronic medical records that were linked to USON retail pharmacy database. Pts who were enrolled in clinical trials or receiving care for other primary tumors were excluded. Results: Pt characteristics: N=134; median age = 64 years (range 41–87); ECOG PS 0/1 = 85%; clear cell RCC = 81%; and nephrectomy = 61%. Objective response rate was 16%. Overall survival (OS) was 15.4 months (95% confidence interval 11.9–20.8). Median treatment duration was 4 cycles (range 1–19): 27 pts (20.1%) received only 1 cycle of sunitinib (23 at full dose [50 mg] and 4 at <full dose); 107 pts (79.9%) received >1 cycle of sunitinib (53 received full dose; 35 started at full dose but were dose-reduced; 14 always received <full dose; 5 started at <full dose but were dose-increased to 50 mg). Overall, 45 pts were dose-reduced, principally (93%) due to toxicities; 67% of all dose reductions occurred in the first 3 cycles. 121 pts discontinued sunitinib after completing at least 1 cycle, mostly due to disease progression (PD; 44%) or toxicities (17%); 74% of all discontinuations occurred within the first 5 cycles. Conclusions: RCC pts in community practices commonly undergo sunitinib dose reductions in the first 3 cycles due to toxicities, and discontinue therapy within the first 5 cycles due to PD. The median number of cycles and OS were lower than those reported in clinical trials (Motzer JCO 2009;27:3584–3590). More selective TKIs are needed to reduce toxicities, optimize dosing, and potentially improve outcomes. Funded by a grant from AVEO Pharmaceuticals, Inc." @default.
• W2747947255 created "2017-08-31" @default.
• W2747947255 creator A5007453606 @default.
• W2747947255 creator A5020368996 @default.
• W2747947255 creator A5023737745 @default.
• W2747947255 creator A5030390401 @default.
• W2747947255 creator A5059219836 @default.
• W2747947255 creator A5072830427 @default.
• W2747947255 creator A5078329114 @default.
• W2747947255 date "2012-05-20" @default.
• W2747947255 modified "2023-09-27" @default.
• W2747947255 title "Sunitinib dosing, toxicity, and outcomes in first-line advanced renal cell carcinoma (aRCC): A U.S. Oncology Network (USON) retrospective study." @default.
• W2747947255 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.e15089" @default.
• W2747947255 hasPublicationYear "2012" @default.
• W2747947255 type Work @default.
• W2747947255 sameAs 2747947255 @default.
• W2747947255 citedByCount "1" @default.
• W2747947255 countsByYear W27479472552014 @default.
• W2747947255 crossrefType "journal-article" @default.
• W2747947255 hasAuthorship W2747947255A5007453606 @default.
• W2747947255 hasAuthorship W2747947255A5020368996 @default.
• W2747947255 hasAuthorship W2747947255A5023737745 @default.
• W2747947255 hasAuthorship W2747947255A5030390401 @default.
• W2747947255 hasAuthorship W2747947255A5059219836 @default.
• W2747947255 hasAuthorship W2747947255A5072830427 @default.
• W2747947255 hasAuthorship W2747947255A5078329114 @default.
• W2747947255 hasConcept C121608353 @default.
• W2747947255 hasConcept C126322002 @default.
• W2747947255 hasConcept C143998085 @default.
• W2747947255 hasConcept C167135981 @default.
• W2747947255 hasConcept C2777288759 @default.
• W2747947255 hasConcept C2777472916 @default.
• W2747947255 hasConcept C2778820342 @default.
• W2747947255 hasConcept C2779490328 @default.
• W2747947255 hasConcept C29730261 @default.
• W2747947255 hasConcept C535046627 @default.
• W2747947255 hasConcept C71924100 @default.
• W2747947255 hasConceptScore W2747947255C121608353 @default.
• W2747947255 hasConceptScore W2747947255C126322002 @default.
• W2747947255 hasConceptScore W2747947255C143998085 @default.
• W2747947255 hasConceptScore W2747947255C167135981 @default.
• W2747947255 hasConceptScore W2747947255C2777288759 @default.
• W2747947255 hasConceptScore W2747947255C2777472916 @default.
• W2747947255 hasConceptScore W2747947255C2778820342 @default.
• W2747947255 hasConceptScore W2747947255C2779490328 @default.
• W2747947255 hasConceptScore W2747947255C29730261 @default.
• W2747947255 hasConceptScore W2747947255C535046627 @default.
• W2747947255 hasConceptScore W2747947255C71924100 @default.
• W2747947255 hasLocation W27479472551 @default.
• W2747947255 hasOpenAccess W2747947255 @default.
• W2747947255 hasPrimaryLocation W27479472551 @default.
• W2747947255 hasRelatedWork W1967487178 @default.
• W2747947255 hasRelatedWork W2034058863 @default.
• W2747947255 hasRelatedWork W2298717328 @default.
• W2747947255 hasRelatedWork W2342120195 @default.
• W2747947255 hasRelatedWork W2480362970 @default.
• W2747947255 hasRelatedWork W2503391584 @default.
• W2747947255 hasRelatedWork W2511080074 @default.
• W2747947255 hasRelatedWork W2511793754 @default.
• W2747947255 hasRelatedWork W2528407746 @default.
• W2747947255 hasRelatedWork W2580987512 @default.
• W2747947255 hasRelatedWork W2587585350 @default.
• W2747947255 hasRelatedWork W2589164886 @default.
• W2747947255 hasRelatedWork W2590340566 @default.
• W2747947255 hasRelatedWork W2602025139 @default.
• W2747947255 hasRelatedWork W2778584590 @default.
• W2747947255 hasRelatedWork W2890863299 @default.
• W2747947255 hasRelatedWork W2905004070 @default.
• W2747947255 hasRelatedWork W2923738693 @default.
• W2747947255 hasRelatedWork W2996164021 @default.
• W2747947255 hasRelatedWork W3093065681 @default.
• W2747947255 isParatext "false" @default.
• W2747947255 isRetracted "false" @default.
• W2747947255 magId "2747947255" @default.
• W2747947255 workType "article" @default.